Winclove eyes 'ear, nose & throat' with probiotic purchase


Dutch firm Winclove Probiotics is extending into ear, nose and throat (ENT) treatment with the purchase of 10 probiotic strains.

Alfa-streptococcal strains were purchased in combination with Lactobacillus strains and accompanying patent from Probac, a Swedish manufacturer of probiotics that target bacterial infections of the ear, nose and throat, the gastrointestinal tract and the immune system.

Administering probiotics targeted for use in ENT prevention directly after first treatment with antibiotics helps rapid regrowth of natural microbiota and commensal bacteria to protect against recurrent pathogens, Winclove said.

Winclove has previously won claims for a multi-strain probiotic blend for products targeting vaginal health under European Union medical devices legislation and can be used in the EU's 28 member states.

Targeted treatment

Dr Coline Gerritsen, scientist for genomics and product development at Winclove Probiotics, told us that the 10 strains are different from others Winclove uses in that they have been specifically isolated from the nasopharynx, the location in the human body that the company’s new products will target.

They have been selected for their potential to inhibit the specific pathogens that play a role in recurrent bacterial middle ear and thoat infections,” she said.

We are looking into the possibilities to register and market a nasal spray containing a selection of the strains acquired, as a medical device.

When we succeed in registering this product as a medical device this will mean it will be applied topically.”

Gerritsen said she was confident of successful registration for the nasal spray as a medicinal device given the company’s previous experience attaining approved status with its portfolio of products for vaginal application.

A delicate blend

Winclove’s Ecologic FEMI+ range was developed following experimentation with more than 30 different probiotic strains before determining the combination of six strains its scientists found to be most effective.

A study published in July suggested probiotic strains are effective against recurrent vaginal infections when used with prescribed medication. The study used Bifodan’s EcoVag probiotic.

Winclove expects to bring a product using the strains to the market in the second half of 2016.

Related News

Only one in 16 probiotic products tested exactly matched the bifidobacterial species claimed on pack. Photo credit:

Quality control of probiotics is lacking, study suggests

Government-backed researchers develop low GI, polyphenols-rich probiotic pasta. Photo credit: / DawidKasza

‘Mamma mia!’ Italian researchers say ‘si’ to probiotic pasta

"Talking about these things there are always questions that start to come into your head as a woman like: ‘Is this normal?’" ©

Overcoming the taboo of vaginal health – the next frontier of probiotics

The team found that ACEMg supplementation influenced the progression of genetic hearing loss. (©

Supplements may delay genetic hearing loss in children

Multispecies approach builds a better probiotic team, Winclove believes

Multispecies approach builds a better probiotic team, Winclove believes


Danish probiotic player expands operations

Related Products

See more related products

Submit a comment

Your comment has been saved

Post a comment

Please note that any information that you supply is protected by our Privacy and Cookie Policy. Access to all documents and request for further information are available to all users at no costs, In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information maybe shared with the owners of that document or information.